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Abstract 
Renal dysfunction results in the accumulation of various uremic toxins, including 
indoxyl sulphate (IS), and is a major risk factor for atrial fibrillation (AF). Experimental 
studies have demonstrated that IS exacerbates atrial remodelling via oxidative stress, 
inflammation, and fibrosis. However, its clinical impact on AF-promoting cardiac 
remodelling has not been described. Therefore, the purpose of this study was to clarify 
the relationship between basal IS levels and the 1-year outcomes after catheter ablation 
for the treatment of AF. Our prospective observational study included data from 125 
patients with AF who underwent catheter ablation. Over a 1-year follow-up period, AF 
recurrence was identified in 21 patients. The 1-year AF-free survival was significantly 
lower in patients with high serum IS levels (≥ 0.65 μg/mL) than in those with low IS 
levels (60.1 ± 10.4% versus 85.2 ± 3.9%, P = 0.007). Univariable analysis identified 
that an IS concentration ≥ 0.65 μg/mL was associated with AF recurrence (hazard ratio 
[HR] = 3.10 [1.26-7.32], P = 0.015), and this association was maintained in multivariate 
analysis (HR = 3.67 [1.13-11.7], P = 0.031). Thus, in patients undergoing AF ablation, 
serum IS levels at baseline independently predict the recurrence of arrhythmia. 
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Abbreviations 
AAD; anti arrhythmic drug 
ACEI; angiotensin-converting-enzyme inhibitor 
AF; atrial fibrillation 
ARB; angiotensin receptor antagonist 
BNP; B-type natriuretic peptide 
CI; confidence interval  
CKD; chronic kidney disease 
CrCl; creatinine clearance 
CRP; C-reactive protein 
ECG; Electrocardiogram 
eGFR; estimated glomerular filtration rate 
HR; hazard ratio 
IS; indoxyl sulphate 
LA; left atrium 
LAVI; left atrial volume index 
LVEF; left ventricular ejection fraction 
MCP-1; monocyte chemoattractant protein 1 
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PV; pulmonary vein 
PVI; pulmonary vein isolation 
RFCA; Radiofrequency catheter ablation 
SD; standard deviation 
TGF-β1; transforming growth factor β1 
α-SMA; α-smooth muscle actin 
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Introduction 
Several clinical trials have reported a close association between atrial fibrillation (AF) 
and chronic kidney disease (CKD).1–5 For example, the burden of AF is increased 
among patients with CKD, and AF itself increases as a function of CKD severity. The 
relationship between renal function and AF recurrence after catheter ablation for AF 
was addressed in recent reports.6–8 Patients with a lower estimated glomerular filtration 
rate (eGFR) at baseline had a greater risk of recurrence after radiofrequency catheter 
ablation for AF. Atrial remodelling due to CKD was thought to be responsible for the 
poor outcome after AF ablation in patients with CKD; however, the exact mechanism of 
this association remains to be elucidated. 
Indoxyl sulphate (IS) is among the most representative uremic toxins derived 
from the metabolism of dietary protein by the gut microbiota and has been implicated in 
the pathogenesis of various cardiovascular diseases,9–11 including AF.12 Experimental 
studies in animal models have shown that IS can exacerbate AF via its effect on cardiac 
fibrosis and inflammation, with enhanced oxidative stress and reduced anti-oxidative 
defense.13,14 These effects have been shown to induce arrhythmogenesis in pulmonary 
veins, sinoatrial nodes, and atria isolated from rabbit hearts.15 Recently, Aoki et al.16 
demonstrated, in a rat model of CKD, that IS increases the inducibility of AF, and that 
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circulating levels of IS can be significantly attenuated by using an absorbent of uremic 
toxins, such as AST-120. Thus, it is plausible that IS may contribute to atrial 
remodelling, although there is limited clinical evidence in support of the association 
between IS and AF.  
Therefore, the aim of our study was to investigate the relationship between IS 
and recurrent AF in patients after radiofrequency catheter ablation (RFCA) for AF.  
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Methods 
Study population 
This prospective observational study was conducted at the University of Tsukuba 
Hospital, Tsukuba, Japan, between April 2009 and March 2011. We enrolled 125 
consecutive patients with non-valvular AF scheduled for RFCA for AF. Patients who 
had hemodynamically significant (moderate-to-severe) valvular disease, thrombus in the 
left atrium (LA), uncontrolled thyroid dysfunction, pre-procedural significant coronary 
artery stenosis, a previous myocardial infarction or cardiac surgery in the previous 3 
months, contraindications to anticoagulant therapy, stage 4 or 5 CKD, or pregnancy 
were excluded.  
All enrolled patients had symptomatic paroxysmal or persistent AF and had 
not responded to treatment with one or more antiarrhythmic drugs. Long-standing 
persistent AF was defined as any AF episode lasting for longer than 1 year. A detailed 
medical history regarding AF and related cardiovascular and/or systemic conditions was 
obtained from all patients. The CHADS2 score was calculated for each patient based on 
a point system, as previously described.17 Transthoracic echocardiography was also 
performed to assess left ventricular function and the left atrial volume index (LAVI) 
before RFCA.  
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The study was in compliance with the principles outlined in the Declaration of 
Helsinki and was approved by Ethics Committee, University of Tsukuba Hospital. 
Before ablation, written informed consent was obtained from all the patients.  
 
Study endpoint 
The endpoint of this study was recurrence of AF or atrial tachycardia after a blanking 
period of 3 months. 
 
Serum IS concentration 
Blood samples were collected from patients just before ablation and serum was stored at 
-80°C. Serum levels of IS and indole-3 acetic acid (IAA) were measured by 
reversed-phase high-performance liquid chromatography using a conventional 
octadecylsilyl silica column and a fluorescence detector, according to a previously 
described method, with minor modifications.18 The coefficients of variation for 
intra-day and inter-day assays were < 3%.  
 
 
 
 10 
Classification of CKD 
Classification of the CKD stage was determined using the eGFR, calculated at baseline. 
The eGFR was calculated using the estimation equation for Japanese patients with 
CKD.19 This equation calculates the eGFR from serum creatinine, adjusted for age and 
sex, using the following formula: (eGFR [mL/min/1.73 m2] = 194 × age-0.287 × serum 
creatinine-1.094 × [0.739 for women]). The study population was divided into three 
subgroups: patients with an eGFR ≥ 90 mL/min/1.73 m2 (CKD stage 1), patients with 
an eGFR between 60 and 89.9 mL/min/1.73 m2 (CKD stage 2), and patients with an 
eGFR between 30 and 59.9 mL/min/1.73 m2 (CKD stage 3). The creatinine clearance 
(CrCl) was evaluated using the Cockcroft–Gault formula: CrCl (mL/min) = ([140 - age] 
× body weight [kg] × [0.85 if female])/(72 × serum creatinine [mg/dL]).  
 
Catheter ablation 
Procedures were performed under general anaesthesia, aiming at an anticoagulation 
time of 300 s. An irrigated-tip catheter was used to deliver radiofrequency energy in all 
patients. A circular lasso catheter was used to confirm the pulmonary vein (PV) and to 
map the LA area. After trans-septal puncture, PV isolation (PVI) was performed. After 
PVI, a bidirectional block was systematically obtained in all veins. In the case of 
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persistent AF, complete electrical isolation of the PVs was confirmed after restoration 
of a sinus rhythm. If the AF was sustained or recurred despite the internal cardioversion 
after PVI, a stepwise approach was used, including linear ablation of the LA roof, 
superior vena cava isolation, and/or ablation of complex fractionated atrial 
electrograms. 
 
Follow-up 
Follow-up was performed at 1, 3, 6, and 12 months, or earlier if a patient developed 
symptoms consistent with recurrent AF. The average follow-up period was 11.7 months 
(range, 3.2 to 12 months). Recurrence was defined as any evidence of an episode of 
atrial arrhythmia (atrial fibrillation, atrial tachycardia and atrial flatter) lasting for more 
than 30s after a 3-month blanking period. Atrial arrhythmia was documented by 
3-minutes ECG or Holter-ECG performed at out-patients’ clinics including referral 
origin medical institutions, or by interrogating pacemaker log if 
pacemaker-implanted-patients. 
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Statistical analysis 
Analyses were performed using JMP software (version 10). Values are reported as the 
mean ± standard deviation (SD) for continuous variables, and proportions for 
categorical variables. The optimal cut-off point was determined by the maximum 
Youden index based on receiver operating characteristic (ROC) curve analysis, and 
areas under the ROC curve (AUCs) were calculated. The association between serum 
levels of IS or IAA and other factors was evaluated using Pearson’s correlation 
coefficients. Differences between continuous values were assessed using an unpaired, 
two-tailed, t-test for normally distributed continuous variables, and a Mann–Whitney 
test for skewed variables. The chi-square statistic was used for testing relationships 
between categorical variables. The association between baseline variables and AF 
recurrence was evaluated using univariate and multivariate Cox proportional hazards 
analysis. AF-free survival curves were analysed according to the Kaplan–Meier method 
and compared by the log-rank test. A P-value < 0.05 was considered significant. 
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Results 
Study population 
Of the 125 consecutive patients with AF enrolled, 20 were excluded from the analysis 
due to missing pre-echocardiographic data (5 patients) and because of a lack of 
follow-up (15 patients). Relevant data of the remaining 105 patients (83.8% men, mean 
age: 60.0 ± 10.8 years) included in the analysis are reported in Table 1. Over the 1-year 
follow-up after ablation, 21 (20.0%) patients developed AF recurrence (AF in 16, 
uncommon atrial flutter in 1, and atrial tachycardia in 4 patients). There were no 
significant differences in baseline IS and IAA levels between patients who developed 
AF-recurrence and those who did not (IS, 0.51 ± 0.33 vs 0.43 ± 0.31 μg/mL, P = 0.27; 
IAA, 0.14 ± 0.05 vs 0.16 ± 0.10 μg/mL, P = 0.31, respectively). After calculating the 
maximum Youden index (sensitivity + specificity - 1) and the AUC, the optimal cut-off 
values of serum levels of IS and IAA were found to be 0.65 μg/mL and 0.17 μg/mL, 
respectively (Table 2).  
 
Relationship of serum IS levels with renal function and age  
Serum IS levels were significantly increased in patients with CKD stage 3 (Figure 1). 
However, the correlations of serum IS levels with eGFR (r = -0.295, P = 0.002) and 
 14 
CrCl (r = -0.263, P = 0.007) were weak (Figure 2a and 2b). IS levels were also weakly 
correlated with age (r = 0.253, P = 0.009; Figure 2c).  
IAA is also a uremic toxin and belongs to the family of indolic uremic solutes, 
such as IS. Serum levels of IAA were positively correlated with those of IS (r = 0.443, 
P < 0.001; Figure 3). In this cohort, unlike IS, IAA levels did not differ statistically 
significantly among patients with CKD stage 1, 2, and 3 (Figure 4). IAA levels were 
weakly correlated with eGFR (r = -0.255, P = 0.009), but not with CrCl (r = -0.102, P = 
0.30) or age (r = -0.029, P = 0.77) (Figure 5).  
 
Demographic and clinical characteristics of patients with high IS levels 
Among the 105 patients in our study group, 23 patients (21.9%) were categorized into 
the high IS (≥ 0.65 μg/mL) and 82 patients (78.1%) into the low IS group (< 0.65 
μg/mL; Table 1) according to the optimal cut-off value. There were no significant 
differences in sex or age between the two groups. The duration after diagnosis of AF 
was significantly longer in the high IS group (P = 0.010). Patients with high IS levels 
had lower eGFR (P = 0.019), an increased LAVI (P = 0.012), an elevated BNP (P = 
0.042), and were more likely to have been treated with beta-blockers before ablation (P 
= 0.003). After ablation, the proportion of patients taking class III anti-arrhythmic drugs 
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(AAD) was significantly higher in the high-IS group than in the low-IS group (P = 
0.004, Table 4).  
 
AF-free survival  
The 1-year AF-free survival was significantly lower in patients with a high serum IS 
level than in those with a low IS level (60.1 ± 10.4% vs 85.2 ± 3.9%, P = 0.007; Figure 
6a). However, the 1-year AF-free survival did not differ (P = 0.25) between patients 
with high IAA levels (85.9 ± 5.8%) and those with low IAA levels (76.6 ± 5.1%) 
(Figure 7).  
Overall, in our study group, 76 patients (72.4%) underwent a first AF ablation, 
with the remaining 29 (27.6%) undergoing a repeat AF ablation. Among the 29 patients 
with recurrent AF, recovery of electrical conduction between the PVs and the LA was 
identified in 26 patients (89.7%). The serum IS level of patients who underwent a repeat 
AF ablation was higher than that of patients who underwent a first AF ablation (0.57 ± 
0.41 μg/mL vs. 0.40 ± 0.26 μg/mL; P =0.014) 
Among patients who underwent a first AF ablation, the 1-year estimates of 
AF-free survival were 47.6 ± 13.8% for those with a high serum IS level and 85.5 ± 
4.5% for those with a low IS level (P = 0.003; Figure 6b). In contrast, among patients 
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who underwent a repeat AF ablation (Figure 6c), the 1-year AF-free survival did not 
significantly differ (P = 0.58) between patients with high IS levels (77.9 ± 13.9%) and 
those with low IS levels (84.2 ± 8.4%).   
 
Predictive value of IS in AF recurrence 
On univariate analysis, an IS level ≥ 0.65 μg/mL was associated with an increased risk 
of AF recurrence (hazard ratio [HR]: 3.10, 95% CI: 1.26–7.32; P = 0.015; Table 3). 
After adjustment for age and sex, an IS level ≥ 0.65 μg/mL remained associated with 
increased risk of AF recurrence (HR: 3.76, 95% CI: 1.52–9.03; P = 0.005; Table 3). In 
the multivariate Cox proportional hazard model, adjusted for age, sex, duration after AF 
diagnosis, beta-blocker use before ablation, LAVI, BNP, Class III AAD use after 
ablation, as well as eGFR or CKD stage, an IS level ≥ 0.65 μg/mL remained as an 
independent predictor of AF recurrence (HR 3.60, 95% CI: 1.12–11.0, P = 0.032; and 
HR 3.67, 95% CI: 1.13–11.7, P = 0.031, respectively; Table 3).  
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Discussion 
In this prospective observational study, we identified high IS levels as a strong and 
independent predictor of AF recurrence in patients undergoing successful catheter 
ablation. To the best of our knowledge, this association of uremic toxins with the 
outcomes of AF ablation has not been described previously.   
The high AF recurrence rate after ablation in patients with CKD is indicative 
of a possible involvement of uremic toxins in AF pathogenesis. However, no clinical 
studies to date have demonstrated the involvement of uremic toxins in AF recurrence. 
Here, we showed that patients with a higher IS levels exhibited a higher rate of AF 
recurrence after ablation, with serum IS being a significant predictor of AF recurrence, 
even after adjustment for eGFR or the stage of CKD. Thus, it seems that IS has a 
predictive role in AF recurrence.  
In recent years, increasing attention has been paid to the relationship between 
IS and cardiovascular diseases among patients with CKD. Barreto et al.20 reported that a 
higher serum level of IS was associated with an increased overall mortality and 
cardiovascular-specific mortality among patients with CKD. Furthermore, Lin et al.21 
indicated that IS was a valuable marker in predicting cardiovascular events in patients 
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with advanced CKD. Other researchers have reported association of a high IS level with 
increased risk of LV diastolic dysfunction.22,23  
In our study cohort, the IS concentration correlated poorly with eGFR (Figure 
1), which was consistent with the findings from other groups.24,25 IS is a gut-derived 
uremic toxin and factors other than the GFR, such as renal tubular secretion, diet and 
intestinal absorption, and gut microbiota metabolism, may affect IS concentration.26 
Recent animal studies have revealed the causative role of IS in promoting AF 
remodelling. Chen et al.15 reported that IS induced the occurrence of delayed 
after-depolarizations and burst firing in PVs isolated from rabbits. They also showed 
that IS-treated PV cardiomyocytes had a larger Ca2+ leak than control PV 
cardiomyocytes.15 Aoki et al.16 showed that, in rat models of renal failure induced by 
5/6 nephrectomy, administration of AST-120, which is commonly used in clinical 
practice as an absorbent of uremic toxins, attenuated oxidative stress, inflammation, and 
fibrosis in the LA, and decreased AF inducibility in vivo. In cultured atrial fibroblasts, 
incubation with IS upregulated the expression of oxidative stress markers NOX2/NOX4 
and malondialdehyde, along with an increase in inflammatory and profibrotic signalling 
molecules, such as monocyte chemoattractant protein 1 (MCP-1), transforming growth 
factor β1 (TGF-β1), α-smooth muscle actin (α-SMA), and collagen I.16 These results 
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indicate a direct effect of IS on the progression of the AF substrate. Therefore, IS may 
become a novel therapeutic target for AF.  
It has been well known that dietary protein intake and fluid balance when 
blood samples were collected affect to the level of eGFR or CrCl. Such environment 
factors could easily affect to the patients with stage 1-2 CKD, because the level of renal 
dysfunction is not so different between the patients with stage 1 CKD and those with 
stage 2 CKD. On the other hands, patients with stage 3 CKD have moderate renal 
dysfunction and less affected by such environment factors. For this reason, AST 120 
can be prescribed for patients with over stage 3 CKD in the clinical setting. Though the 
population of this study was patients with stage 1-3 CKD, patients with just stage 3 
CKD must be focused on from the viewpoint of effect of AST120 to the prevention of 
promoting AF. Further more investigation will be needed to determine whether AST 
120 can prevent AF recurrence.  
The prevalence of AF among a large population of patients with CKD was 
found to be 2- to 3-fold higher than that in the general population.27,28 Moreover, the 
prevalence of AF among dialysis patients has been reported to range between 7% and 
27%,29–32 as compared to 0.4% to 1.0% in the general population,33 indicating that 
haemodialysis may not eliminate the risk of AF in CKD. Therefore, non-dialyzable 
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uremic factors were considered responsible for AF-promoting remodelling. IS is a 
poorly dialyzable uremic toxin due to its high protein binding. Even after haemodialysis, 
the serum IS levels still remain high.34 Therefore, accumulating IS may directly 
contribute to atrial remodelling in patients with CKD. In this study, patients with stage 4 
or 5 CKD or received dialysis were excluded. However, from those aspects, it attracts to 
great interest whether high IS levels can also predict AF recurrence in patients with 
severe renal dysfunction. Further studies, which target such population, will be needed. 
In addition, in this study cohort, blood samples were collected at a single time 
point just before catheter ablation and the transition of level of IS after ablation was not 
considered at all. Serum level of IS at the time point of recurrent AF may be also an 
important factor to investigate the mechanism how IS promote AF. Furthermore, we just 
described the association of uremic toxins with AF recurrence, not AF occurrence in 
this study design. To investigate the serum level of normal population and the transition 
of serum level of IS will reveal new pathology of AF mechanism.  
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Limitations 
The study had some limitations. First, compared to patients in the low IS level group, 
the duration after AF diagnosis had been longer in the cohort of patients with high IS 
levels; this group also had a greater prevalence of beta-blocker use, increased LAVI, 
and worse renal function, which would be sources of possible residual confounding 
factors. Furthermore, our study evaluated a heterogeneous population, including 
patients with paroxysmal as well as persistent AF. Because of the small sample size, no 
separate analysis was possible between these different groups. Consequently, we cannot 
rule out different biomarker patterns between these two entities of AF. Second, the 
diagnosis of AF recurrence was based on the occurrence of symptoms and periodic and 
occasional ECG recordings and Holter ECG findings. Therefore, some patients with 
asymptomatic AF recurrence might have been missed. Third, our cohort included 
individuals who underwent AF ablation at our institution between 2009 and 2011. 
During that period, advanced technologies that are widely used today, including the 
contact force-sensing catheter and balloon ablation, were not approved for use in Japan. 
These newer technologies have been reported to increase the durability of PV isolation 
and reduce AF recurrence.35,36 Further studies may be needed to determine whether high 
IS levels can predict AF recurrence in the current setting of AF ablation. Fourth, patients 
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who had haemodynamically significant valvular heart disease or stage 4 or 5 CKD, or 
received dialysis were excluded from this study. Further studies are needed to determine 
whether high IS levels can also predict AF recurrence in those patients. Fifth, it has been 
reported that there were some diurnal and inter-day variations in the circulating IS 
concentrations,37 and dietary protein intake affected the IS concentrations.38 However, 
in this study, blood samples were collected at a single time point, but were not collected 
at the same time of the day for all patients, and were not standardized with respect to 
food intake. Finally, this study was performed in a single centre with a relatively small 
sample size and a short follow-up period. Therefore, further studies with more patients 
and a longer follow-up period may be needed to confirm our study results. 
 
 
Conclusion 
Serum IS levels are associated with recurrence of AF after catheter ablation. Therefore, 
the IS level should be considered in the prediction of recurrence after ablation. 
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Tables 
Table 1. Baseline characteristics 
 
All  
(n = 105) 
IS ≥ 0.65 μg/mL 
(n = 23) 
IS < 0.65 μg/mL 
(n = 82) 
P-value 
Age (years) 60.0 ± 10.8 62.9 ± 11.3 59.2 ± 10.6 0.14 
Male sex 88 (83.8) 20 (87.0) 68 (82.9) 0.64 
Body mass index (kg/m2) 23.6 ± 2.9 23.7 ± 3.2 23.6 ± 2.9 0.94 
Paroxysmal AF 69 (65.7) 14 (60.9) 55 (67.1) 0.58 
Long-standing AF >1year 19 (19.1) 7 (30.4) 12 (14.6) 0.082 
Duration of AF history 
(years) 
 
5.5 ± 5.7 8.4 ± 6.9 4.8 ± 5.2 0.010 
Medication     
ACEIs/ARBs 44 (41.9) 10 (43.5) 34 (41.5) 0.86 
Statins 33 (31.4) 5 (21.7) 28 (34.2) 0.26 
Beta-blockers 58 (55.2) 19 (82.6) 39 (47.6) 0.003 
Class I AADs 59 (56.2) 12 (52.2) 47 (57.3) 0.66 
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Class III AADs 34 (32.4) 10 (43.5) 24 (29.3) 0.20 
Class IV AADs 16 (15.2) 2 (8.7) 14 (17.1) 0.32 
 
Hypertension 
 
52 (49.5) 
 
13 (56.5) 
 
39 (47.6) 
 
0.45 
Diabetes mellitus 14 (13.3) 3 (13.0) 11 (13.4) 0.96 
Dyslipidaemia 48 (45.7) 9 (39.1) 39 (47.6) 0.47 
CHADS2 score 0.81 ± 0.84 1.04 ± 0.88 0.74 ± 0.83 0.13 
 
Echocardiogram 
parameters 
    
LVEF (%) 65.2 ± 11.2 66.3 ± 12.4 64.9 ± 10.9 0.62 
LAVI (mL/m2) 36.3 ± 18.3 44.7 ± 22.0 33.8 ± 16.4 0.012 
eGFR  
(mL/min/1.73 m2) 
76.1 ± 18.5 68.2 ± 20.9 78.4 ± 17.3 0.019 
CKD stage    0.021 
Stage 1 19 (18.1) 4 (17.4) 15 (18.3)  
Stage 2 69 (65.7) 11 (47.8) 58 (70.7)  
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Values are given as mean ± SD or number (%). 
AAD, anti arrhythmic drug; AF, atrial fibrillation; ACEI, 
angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor antagonist; BNP, 
B-type natriuretic peptide; CRP, C-reactive protein; eGFR, estimated glomerular 
filtration rate; IS, indoxyl sulfate; LAVI, left atrial volume index; LVEF, left ventricular 
ejection fraction 
  
Stage 3 17 (16.2) 8 (34.8) 9 (11.0) 
 
 
BNP (pg/mL) 78.9 ± 91.6 114.1 ± 111.7 69.5 ± 83.8 0.042 
CRP (mg/mL) 0.097 ± 0.102 0.114 ± 0.111 0.092 ± 0.099 0.34 
IS (μg/mL) 0.45 ± 0.31 0.93 ± 0.25 0.31 ± 0.15 < 0.001 
IAA (μg/mL) 0.16 ± 0.10 0.18 ± 0.07 0.15 ± 0.10 0.097 
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Table 2. Optimal cut-off point based on AF recurrence 
 Median value Range AUC Cut-off value 
IS (μg/mL) 0.36 0–1.74 0.576 0.65 
IAA (μg/mL) 0.13 0.04–0.56 0.522 0.17 
AF; atrial fibrillation, AUC; area under the curve, IAA; indole-3 acetic acid,  
IS; indoxyl sulphate 
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Table 3. 
Impact of a level of indoxyl sulphate ≥ 0.65 μg/mL on atrial fibrillation recurrence 
 HR 95% CI P-value 
Unadjusted analysis 3.10 1.26−7.32 0.015 
Analysis adjusted for:     
Age and sex 3.76 1.52−9.03 0.005 
Age, sex, duration after diagnosis of AF, beta-blocker 
use before ablation, LAVI, BNP, Class III AAD use 
after ablation, and eGFR 
3.60 1.12−11.0 0.032 
Age, sex, duration after diagnosis of AF, beta-blocker 
use before ablation, LAVI, BNP, Class III AAD use 
after ablation, and CKD stage 
3.67 1.13−11.7 0.031 
AAD, anti-arrhythmic drug; AF, atrial fibrillation; BNP, B-type natriuretic peptide; CI, 
confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular 
filtration rate; HR, hazard ratio; LAVI, left atrial volume index   
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Table 4. Anti-arrhythmic medications after catheter ablation for AF 
AAD; anti-arrhythmic drug, AF; atrial fibrillation, IS; indoxyl sulfate 
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Figures and Figure Legends 
 
 
 
Figure 1. Serum levels of indoxyl sulfate (IS) are increased in patients with 
reduced renal function. CKD; chronic kidney disease. 
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Figure 2a. Relationship between serum levels of indoxyl sulfate (IS) and renal 
function. eGFR; estimated glomerular filtration rate. 
 
 38 
 
Figure 2b. Serum levels of indoxyl sulfate (IS) are increased in patients with 
reduced renal function. CrCl; creatinine clearance. 
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Figure 2c. Relationship between serum levels of indoxyl sulfate (IS) and age. 
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Fig. 3. Relationship between serum levels of IS and IAA.  
IAA = indole-3 acetic acid, IS = indoxyl sulfate. 
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Fig. 4. Serum levels of IAA and CKD stags.  CKD = chronic kidney disease, 
IAA = indole-3 acetic acid. 
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Fig. 5. Correlations between serum levels of IAA and eGFR (a), CrCl 
(b), or age (c).  
CrCl = creatinine clearance, eGFR = estimated glomerular filtration rate, 
IAA = indole-3 acetic acid. 
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Figure. 6. 
Impact of indoxyl sulfate (IS) levels on the recurrence of atrial fibrillation (AF) 
after catheter ablation.  
The AF-free survival rates are shown for the whole cohort according to the IS levels (A). 
The AF-free survival rates are shown for patients undergoing a first AF ablation (B) and 
patients undergoing a repeated AF ablation (C) according to the IS levels. The numbers 
at the bottom of the graph indicates the number of ‘at risk’ patients at each follow-up 
month.  
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Fig. 7. Impact of IAA levels on the recurrence of AF after catheter ablation.  
The numbers at the bottom of the graph indicates the number of ‘at risk’ patients at 
each follow-up month. AF = atrial fibrillation, IAA = indole-3 acetic acid. 
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